Pembrolizumab, Olaparib, and Temozolomide for People with Glioma
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Glioma
DRUG: Pembrolizumab|COMBINATION_PRODUCT: Olaparib and Temozolomide
overall response rate (Cohort A), The response will be determined as outlined in the RANO and iRANO., up to 2 years
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.